ENTITY

International Stem Cell (ISCO US)

7
Analysis
Health Care • United States
International Stem Cell Corporation develops therapeutic and research products in the biotechnology industry. The Company seeks to use human cells for use in the treatment of several diseases including diabetes, as well as in liver and retinal diseases.
more
•07 Sep 2020 18:06•Issuer-paid

International Stem Cell - Termination of coverage

Edison Investment Research is terminating coverage on Abacus Health Products (ABCS), ADL Bionatur (BNT), ASIT Biotech (ASIT), GAME Digital (GMD),...

Share
•20 Aug 2018 19:04•Issuer-paid

International Stem Cell - Biomedical sales more than double

International Stem Cell (ISCO) reported Q218 revenues of $3.0m, up 72.4% compared to Q217 mainly due to the biomedical business, which had...

Share
•14 May 2018 19:00•Issuer-paid

International Stem Cell - Moving forward in Parkinson's and TBI

International Stem Cell (ISCO) is an early-stage cell therapy company currently in clinical trials to treat Parkinson’s disease (PD). In November,...

Share
•03 Jan 2018 18:57•Issuer-paid

International Stem Cell - Interim Parkinson’s data

International Stem Cell recently announced interim six-month results from the first cohort of four patients in its Phase I trial of ISC-hpNSC in...

Share
•24 May 2017 18:00•Issuer-paid

Green light for second cohort

International Stem Cell recently announced that the data safety monitoring board (DSMB) for its Phase I trial of ISC-hpNSC in Parkinson’s disease...

Share
No more insights
x